Clinical trials are an essential tool in modern medicine: they are research investigations in which people voluntarily participate in studies for new treatments and interventions to prevent, diagnose or manage blood disorders. Clinical trials are crucial for the development of new medical treatments and help determine if new medicines are effective, safe or better than the current treatments available and aim to answer the following questions in a controlled environment:
Does the treatment work? Is the treatment safe - does it have significant side effects? Is the treatment better that other treatments already available? If better, does it have less side effects? Does it work faster? Is it more cost-effective than other treatments?
Please visit participate in a clinical trial for details on how to participate in a trial, or contact us for further information. Summaries of PBI's previous clinical trials can be found in our archived projects; our current active clinical trials are listed below.
To learn more about participating in a clinical trial, read our new patient information booklet.
Multiple myeloma (MM) is a cancer of the blood's plasma cells. This is a study to determine the safety, efficacy, and pharmacokinetics of Etentamig in adult participants with MM. Read more
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approxi Read more
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo. Read more
The main aim of this study is to learn whether mezagitamab, when given just under the skin (subcutaneously [SC]), is effective in keeping the platelet count of adults with ITP stable when compared to a placebo. Participants who complete the TAK-079-3002 study or do not have any response to study treatment by week 16 (according to study criteria) will be given the opportunity to participate in a continuation study to receive open label mezagitamab. Read more
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab [for CLL only] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i). Read more
This study will assess the safety and preliminary efficacy of JBI-802 in subjects with myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms with thrombocytosis. Read more
This study will compare the effectiveness of either Talquetamab plus Pomalidomide or Talquetamab plus Teclistamab with Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone. Read more
This study will evaluate Sapablursen in patients with polycythemia vera. Read more
This study is an open-label study of Povetacicept in subjects with autoimmune cytopenias. Read more
This study will compare treatment with Abelacimab to apixaban on venous thromboembolism recurrence and bleeding in patients with cancer associated VTE. Read more
This study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL). Read more
This study is to compare the efficacy and safety of pirtobruitinib to ibrutinib in participants with chronic lymphocytic leukaemia / small lympocytic lymphoma. Read more
This is an observational Cohort study to assess the immune response to the SARS-CoV-2 vaccination and the prevalence of clotting related antibodies in haematology and other immunosuppressed patients. Read more
A Phase 3 study comparing the efficacy and safety of IberDd versus DVd in participants with relapsed or refractory multiple myeloma (RRMM). Read more
This is a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma Read more
This study consists of two parts to explore BGB-16673 recommended dosing. Read more
This is an extension study to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies. Read more
The purpose of this study is to assess the safety, tolerability, and efficacy of BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib. Read more
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Read more
A phase 1/2a study to evaluate safety, pharmacokinetic and pharmacodynamic dose escalation and expansion study of PXS-5505 in patients with primary, postpolycythemia vera or post-essential thrombocythemia myelofibrosis Read more
A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors. Read more
An observational study of patients with Microangiopathic Thrombocytopenia by the Asian-Pacific Microangiopathic Thrombocytopenia (APMAT) Network. Read more
Study the safety and pharmacokinetics of escalating doses of BTCT4465A as a single agent and combined with Atezolizumab in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. Read more
To compare the efficacy and safety of Luspatercept (ACE-536) versus Epoetin Alfa for the treatment of anaemia due to I PSS-R, very low, low or intermediate risk Myelodysplastic syndromes in ESA Naïve subjects who require red blood cell transfusions. Read more